Longer Persistence Seen With Upadacitinib Versus TNFi in Rheumatoid Arthritis

MONDAY, July 6, 2026-- Patients with rheumatoid arthritis (RA) have longer persistence with upadacitinib than tumor necrosis factor inhibitors (TNFi), according to a study published online June 23 in Rheumatology.Denis Choquette, M.D., from the...